GFAP and diabetes mellitus: Quantitation of GLT-1 + GFAP co-labeled cells also showed a significant reduction in the GLT-1 co-labeling with GFAP immunoexpression upto the 12th week of diabetes confirmation, i.e., 2nd week [F(11,359) = 5.705, p = 0.003], 4th week [F(11,359) = 5.560, p = 0.005], 6th week [F(11,359) = 5.850, p = 0.002], 8th week [F(11,359) = 6.452, p ≤ 0.001], 10th week [F(11,359) = 7.883, p ≤ 0.001], and 12th week [F(11,359) = 7.904, p ≤ 0.001] as compared to their respective controls (Figure 11).